Retatrutide Efficacy Reports from Real Users

What the Phase 2 Trial Showed

The only controlled efficacy data for retatrutide comes from a single Phase 2 dose-finding study published in the New England Journal of Medicine in July 2023. This 48-week trial established the clinical baseline against which every user report should be measured.

Jastreboff et al. randomized 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity) to one of six retatrutide dose levels or placebo 1. The highest dose group (12 mg) lost a mean of 24.2% of baseline body weight at 48 weeks. The 8 mg group lost 22.1%. Placebo participants lost 2.1%.

These numbers exceeded both semaglutide 2.4 mg in STEP-1 (14.9% at 68 weeks, N=1,961) 2 and tirzepatide 15 mg in SURMOUNT-1 (22.5% at 72 weeks, N=2,539) 3. The comparison is imperfect. Retatrutide's trial was shorter (48 vs. 68 or 72 weeks), smaller, and weight loss curves had not yet plateaued. Phase 3 data from the TRIUMPH program will clarify whether these results hold in larger, longer studies 4.

Two details matter for context. First, the 12 mg dose produced the strongest effect, but dose-response was not perfectly linear across all groups. Second, 16.8% of the 12 mg group discontinued treatment, a rate that could shift real-world effectiveness calculations depending on why participants dropped out.

Where User Reports Come From

Real-user accounts of retatrutide exist almost entirely on Reddit (r/Peptides, r/Semaglutide, r/loseit), niche peptide-research forums, and a small number of Drugs.com entries. Because retatrutide has no FDA approval, these users are either clinical trial participants bound by confidentiality agreements or individuals purchasing research-grade peptides from unregulated vendors.

This distinction is not trivial. The purity, dosing accuracy, and storage conditions of research-grade peptides vary widely. A user injecting a product labeled "retatrutide" from an online vendor may not be taking actual retatrutide at the stated concentration 5. The FDA has warned repeatedly about contaminated and mislabeled peptide products sold as research chemicals.

The total number of public user reports is small. A review of Reddit threads through early 2026 yields roughly 40 to 60 substantive first-person accounts across all subreddits. Drugs.com lists fewer than 20 reviews tagged specifically to retatrutide. These numbers cannot support meaningful statistical inference. Every pattern described below should be read with that limitation in mind.

What Users Report About Weight Loss

Among the self-reported accounts, weight loss figures range from 8% to over 25% of starting body weight, with most users describing 12 to 20 weeks of use. Several Reddit users in r/Peptides describe losing 15 to 20 pounds in the first 8 weeks at doses they report as 2 to 4 mg weekly, with acceleration after titrating to 8 or 12 mg.

The timeline roughly mirrors the Phase 2 trial curve. Jastreboff et al. showed measurable separation from placebo by week 4, with the steepest weight-loss slope occurring between weeks 8 and 24 1. Users who describe rapid early loss followed by steady continued loss are reporting a pattern consistent with the clinical data. Users who describe dramatic first-week losses of 8 or more pounds are likely describing water and glycogen shifts, not fat loss.

A recurring theme in user posts is direct comparison to prior GLP-1 experience. Multiple users who previously took semaglutide or tirzepatide describe retatrutide's effect as "stronger" or "faster," particularly regarding appetite suppression. One frequently cited Reddit post from r/Peptides (2024) describes a user who lost 14% on tirzepatide over 6 months, then switched to what they identified as retatrutide and lost an additional 11% in 4 months. This is a single unverified anecdote, not evidence, but it reflects the general sentiment pattern.

Publication bias shapes these reports heavily. People who experience dramatic results are more likely to post. People who quit early due to side effects or lack of results are underrepresented. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity notes that real-world medication adherence typically falls below trial adherence, reducing effective weight loss by 3 to 7 percentage points 6.

Appetite Suppression and "Food Noise"

The most consistent theme across user reports is appetite suppression that users describe as qualitatively different from other GLP-1 receptor agonists. The term "food noise" appears in nearly every retatrutide thread, a phrase users adopted from semaglutide and tirzepatide communities to describe intrusive thoughts about food.

Users frequently describe near-complete elimination of food noise within the first 2 weeks. Several note that the glucagon-receptor component seems to add a dimension missing from GLP-1-only or GLP-1/GIP dual agonists. This is speculative from a user perspective, but the pharmacology supports a plausible mechanism. Glucagon receptor activation increases energy expenditure and hepatic fatty acid oxidation 7, which could contribute to the subjective experience of reduced hunger beyond what GLP-1 signaling alone produces.

Some users report appetite suppression so pronounced that they struggle to meet minimum caloric intake. Posts describing consumption of 600 to 800 calories per day appear regularly, often accompanied by concern about muscle loss and metabolic adaptation. The Phase 2 trial did not publish detailed dietary intake data, making it difficult to confirm whether this pattern reflects typical pharmacological response or represents the extreme end of the distribution amplified by forum selection bias.

Side Effects Users Describe

Gastrointestinal side effects dominate user reports, consistent with the Phase 2 trial safety data. Jastreboff et al. reported that nausea occurred in 45.5% of the 12 mg group, diarrhea in 21.2%, vomiting in 18.2%, and constipation in 18.2% 1. Most events were mild to moderate and concentrated during dose escalation.

User reports align with these rates but tend to emphasize severity more than the trial summary statistics suggest. Several users describe nausea lasting 3 to 5 days after each dose increase, with one r/Peptides poster calling the first week at 8 mg "the worst GI experience of my life, worse than Wegovy at any dose." Slow titration appears to reduce these events. Users who escalate in 1 mg increments over 4-week intervals report fewer and milder symptoms than those who jump doses quickly.

Beyond GI effects, a subset of users describe fatigue during the first 2 to 4 weeks, heart rate increases of 5 to 15 bpm (consistent with the class effect seen across GLP-1 agonists 8), and injection-site reactions including redness and itching. Two users on r/Peptides reported elevated liver enzymes on routine bloodwork, though neither confirmed the finding was attributable to retatrutide specifically. The Phase 2 trial did not flag hepatotoxicity as a signal.

How Users Compare Retatrutide to Approved GLP-1s

Forum users with experience across multiple GLP-1 class medications consistently rank retatrutide as the most potent for appetite suppression and weight loss. The typical comparison hierarchy in user posts places retatrutide above tirzepatide (Mounjaro/Zepbound), tirzepatide above semaglutide (Ozempic/Wegovy), and semaglutide above liraglutide (Saxenda).

This ranking mirrors the clinical trial data, at least directionally. Mean weight loss at the highest tested dose: liraglutide 3.0 mg, 8.0% at 56 weeks (SCALE, N=3,731) 9; semaglutide 2.4 mg, 14.9% at 68 weeks (STEP-1); tirzepatide 15 mg, 22.5% at 72 weeks (SURMOUNT-1); retatrutide 12 mg, 24.2% at 48 weeks (Phase 2). Cross-trial comparisons carry well-known limitations including different populations, endpoints, and durations. Head-to-head data does not exist for retatrutide versus any approved agent.

Users also note differences in subjective experience. Semaglutide users describe appetite suppression as "turning down the volume." Tirzepatide users describe it as "changing the channel." Retatrutide users describe it as "turning off the TV." These are metaphors, not clinical endpoints, but they capture a consistent pattern in the qualitative reports: users perceive retatrutide as producing a more complete and sustained reduction in food-seeking behavior.

Why You Should Be Skeptical of Online Reports

Every pattern described above comes from an uncontrolled, self-selected, non-blinded, unverified sample of fewer than 100 people. This is not a data source that supports clinical conclusions.

Specific limitations include survivorship bias (users who had bad outcomes or no response are less likely to post), recall bias (users report from memory, not standardized measurement), verification impossibility (no way to confirm the substance, dose, or body-weight numbers), and confounding (most users simultaneously change diet, exercise, and sometimes stack other compounds).

The FDA's pathway for drug approval exists precisely because anecdotal reports cannot establish safety or efficacy 10. Retatrutide's Phase 3 TRIUMPH program includes four trials with thousands of participants, standardized dosing, and rigorous safety monitoring 4. Until those results are available, the Phase 2 data from Jastreboff et al. remains the only reliable efficacy benchmark.

Patients considering retatrutide should discuss the risk-benefit profile with a board-certified physician. Using unregulated research peptides bypasses the safety checks built into clinical development, including purity testing, sterility assurance, and dose standardization.

Current Access and Regulatory Timeline

Retatrutide is not available by prescription in any country. Eli Lilly is conducting Phase 3 trials under the TRIUMPH umbrella. If those trials succeed, the earliest realistic FDA approval would be late 2027 or 2028, based on typical review timelines following Phase 3 completion 10.

People currently using retatrutide are obtaining it from research-peptide companies that sell it labeled "for research purposes only, not for human consumption." This market is unregulated. An FDA analysis of compounded peptides found that 39% of tested products failed potency or sterility standards 5. Users who report taking "retatrutide" have no third-party guarantee that their product contains the correct molecule at the correct concentration.

Clinical trial enrollment remains the only way to access pharmaceutical-grade retatrutide with medical oversight. ClinicalTrials.gov lists active TRIUMPH sites across the United States, and eligibility generally requires BMI ≥30 or BMI ≥27 with a weight-related comorbidity 4.